Evidence map›Paper›PMID 30808745›Full record

ArticleProceedings of the National Academy of Sciences of the United States of America2019

Signaling pathway of globo-series glycosphingolipids and β1,3-galactosyltransferase V (β3GalT5) in breast cancer.

Po-Kai Chuang, Michael Hsiao, Tsui-Ling Hsu, Chuan-Fa Chang, Chung-Yi Wu, Bo-Rui Chen, Han-Wen Huang, Kuo-Shiang Liao, Chen-Chun Chen, Chi-Long Chen and 8 more

Open access · bronzeAbstract read
In one paragraph

Article in Proceedings of the National Academy of Sciences of the United States of America, 2019. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 37 papers.

0numbers the graph read from it
0cells of the map it votes in
37citing papers in PubMed
3.3field-weighted citation impact, top 7% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

37 citing papers in PubMed, 63 citations in OpenAlex.

  1. Trial
  2. Article
  3. Glycan Markers of Pluripotent Stem Cells.Advances in experimental medicine and biology · 2026
    Review
  4. Article
  5. Article
  6. Article
  7. Article
  8. Increased expression of SSEA-4 on TKI-resistant non-small cell lung cancer with EGFR-T790M mutation.Proceedings of the National Academy of Sciences of the United States of America · 2024
    Article
  9. Article
  10. Review
  11. Article
  12. Review
  13. Article
  14. Review
  15. Article
  16. Review
  17. Review
  18. Review
  19. Article
  20. Therapeutic vaccines for breast cancer: Has the time finally come?European journal of cancer (Oxford, England : 1990) · 2022
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

18 authors at 5 institutions in 1 country.

Po-Kai ChuangGenomics Research Center, Academia Sinica, Taipei, 11529, Taiwan.
Michael HsiaoGenomics Research Center, Academia Sinica, Taipei, 11529, Taiwan.
Tsui-Ling HsuGenomics Research Center, Academia Sinica, Taipei, 11529, Taiwan.
Chuan-Fa ChangInstitute of Basic Medical Science, National Cheng Kung University, Tainan, 70101, Taiwan.
Chung-Yi WuGenomics Research Center, Academia Sinica, Taipei, 11529, Taiwan.ORCID 0000-0002-5233-4454
Bo-Rui ChenGenomics Research Center, Academia Sinica, Taipei, 11529, Taiwan.
Han-Wen HuangGenomics Research Center, Academia Sinica, Taipei, 11529, Taiwan.
Kuo-Shiang LiaoGenomics Research Center, Academia Sinica, Taipei, 11529, Taiwan.
Chen-Chun ChenGenomics Research Center, Academia Sinica, Taipei, 11529, Taiwan.
Chi-Long ChenDepartment of Pathology, College of Medicine, Taipei Medical University, Taipei, 11031, Taiwan.
Shun-Min YangInstitute of Physics, Academia Sinica, Taipei, 11529, Taiwan.
Chiung Wen KuoResearch Center for Applied Sciences, Academia Sinica, Taipei, 11529, Taiwan.
Peilin ChenResearch Center for Applied Sciences, Academia Sinica, Taipei, 11529, Taiwan.
Ping-Tzu ChiuOBI Pharma, Inc., Taipei, 11561.
I-Ju ChenOBI Pharma, Inc., Taipei, 11561.
Jiann-Shiun LaiOBI Pharma, Inc., Taipei, 11561.
Cheng-Der Tony YuOBI Pharma, Inc., Taipei, 11561.
Chi-Huey WongGenomics Research Center, Academia Sinica, Taipei, 11529, Taiwan; chwong@gate.sinica.edu.tw.
Genomics Research Center, Academia Sinica · TWNational Yang Ming Chiao Tung University · TWResearch Center for Applied Science, Academia Sinica · TWInstitute of Physics, Academia Sinica · TWNational Cheng Kung University · TW

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The globo-series glycosphingolipids (GSLs) SSEA3, SSEA4, and Globo-H specifically expressed on cancer cells are found to correlate with tumor progression and metastasis, but the functional roles of these GSLs and the key enzyme β1,3-galactosyltransferase V (β3GalT5) that converts Gb4 to SSEA3 remain largely unclear. Here we show that the expression of β3GalT5 significantly correlates with tumor progression and poor survival in patients, and the globo-series GSLs in breast cancer cells form a complex in membrane lipid raft with caveolin-1 (CAV1) and focal adhesion kinase (FAK) which then interact with AKT and receptor-interacting protein kinase (RIP), respectively. Knockdown of β3GalT5 disrupts the complex and induces apoptosis through dissociation of RIP from the complex to interact with the Fas death domain (FADD) and trigger the Fas-dependent pathway. This finding provides a link between SSEA3/SSEA4/Globo-H and the FAK/CAV1/AKT/RIP complex in tumor progression and apoptosis and suggests a direction for the treatment of breast cancer, as demonstrated by the combined use of antibodies against Globo-H and SSEA4.

Indexed as

Antigens, Tumor-Associated, CarbohydrateApoptosisBreast NeoplasmsCaveolin 1Disease ProgressionFas-Associated Death Domain ProteinFemaleFocal Adhesion Protein-Tyrosine KinasesGalactosyltransferasesGene Expression Regulation, NeoplasticGlycosphingolipidsHumansMacromolecular SubstancesMembrane MicrodomainsMiddle AgedProto-Oncogene Proteins c-aktAntigens, Tumor-Associated, CarbohydrateB3GALT5 protein, humanCaveolin 1FADD protein, humanFas-Associated Death Domain ProteinFocal Adhesion Protein-Tyrosine KinasesGalactosyltransferasesGlobo-HGlycosphingolipidsMacromolecular SubstancesProto-Oncogene Proteins c-aktSaporinsstage-specific embryonic antigen-3stage-specific embryonic antigen-4Stage-Specific Embryonic AntigensFAKGlobo-HSSEA3SSEA4β3GalT5

Identifiers

PMID30808745
PMCPMC6397564
OpenAlexW2914292229

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.